Healthcare Technology Featured Article

November 28, 2012

Novo Nordisk Introduces Mobile App for Enhanced Medical Care



Earlier today, Novo Nordisk announced the introduction of a mobile application (app), HemaGo. This app helps individuals with hemophilia, while also helping their caregivers monitor the details of treatment, including medications, dosing, bleed information and the impact of hemophilia on life events.  In order for more than one family member to be able to use the app, multiple profiles are enabled.

HemaGo helps track multiple medications, set reminders for treatment or doctor's appointments. Moreover, HemaGo can be used to record factor usage and reason for infusion; the type, location and duration of bleeding events; and pain scores, including the impact of the bleeding episode on the individual's participation in work or school. 

"For the first time, individuals can track virtually every aspect of living with a bleeding disorder, regardless of their medication or disorder. We've created a first in class offering that provides benefits to all hemophilia patients and healthcare professionals,” said Eddie Williams, corporate vice president, Biopharmaceuticals.

Individuals at the site, have access to comprehensive reporting features, including treatment logs, bleed logs, and quality of life reports.  This information may be shared with the individual's healthcare team, including their hemophilia treatment center and home healthcare company. Novo Nordisk does not have access to patient-specific information. 

In order for the individual source not to be identified, data has been stripped so that the company's access is restricted to generic information ("de-identified") which is in accordance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy and Security Rules.

To enable patients who choose the option to link their diary data with their other medical records on ATHN's national database of bleeding disorder treatment information, Novo Nordisk is working with the American Thrombosis and Hemostasis Network (ATHN). HemaGo was developed with the participation of Novo Nordisk's Consumer Council, which is comprised of bleeding disorder community members.




Edited by Brooke Neuman




comments powered by Disqus


FREE eNewsletter

Click here to receive your targeted Healthcare Technology Community eNewsletter.
[Subscribe Now]

From White Paper Library